当前位置：
X-MOL 学术
›
Ther. Adv. Med. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis.
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2023-09-15 , DOI: 10.1177/17588359231193732 Maria Luisa Gasparri 1, 2 , Sara Albasini 3 , Marta Truffi 3 , Karin Favilla 4 , Barbara Tagliaferri 3 , Francesca Piccotti 3 , Daniela Bossi 3 , Giulia Armatura 5 , Arianna Calcinotto 6, 7 , Corrado Chiappa 8 , Francesca Combi 9, 10 , Annalisa Curcio 11 , Angelica Della Valle 12 , Guglielmo Ferrari 13 , Secondo Folli 14 , Matteo Ghilli 15 , Chiara Listorti 14 , Stefano Mancini 16 , Peter Marinello 5 , Simone Mele 13 , Anna Pertusati 16 , Manuela Roncella 15 , Lorenzo Rossi 2, 17 , Francesca Rovera 8 , Silvia Segattini 10 , Adele Sgarella 18, 19 , Daniela Tognali 11 , Fabio Corsi 20, 21
Therapeutic Advances in Medical Oncology ( IF 4.9 ) Pub Date : 2023-09-15 , DOI: 10.1177/17588359231193732 Maria Luisa Gasparri 1, 2 , Sara Albasini 3 , Marta Truffi 3 , Karin Favilla 4 , Barbara Tagliaferri 3 , Francesca Piccotti 3 , Daniela Bossi 3 , Giulia Armatura 5 , Arianna Calcinotto 6, 7 , Corrado Chiappa 8 , Francesca Combi 9, 10 , Annalisa Curcio 11 , Angelica Della Valle 12 , Guglielmo Ferrari 13 , Secondo Folli 14 , Matteo Ghilli 15 , Chiara Listorti 14 , Stefano Mancini 16 , Peter Marinello 5 , Simone Mele 13 , Anna Pertusati 16 , Manuela Roncella 15 , Lorenzo Rossi 2, 17 , Francesca Rovera 8 , Silvia Segattini 10 , Adele Sgarella 18, 19 , Daniela Tognali 11 , Fabio Corsi 20, 21
Affiliation
Background
Systemic inflammatory markers draw great interest as potential blood-based prognostic factors in several oncological settings.
Objectives
The aim of this study is to evaluate whether neutrophil-to-lymphocyte ratio (NLR) and pan-immune-inflammation value (PIV) predict nodal pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in node-positive (cN+) breast cancer (BC) patients.
Design
Clinically, cN+ BC patients undergoing NAC followed by breast and axillary surgery were enrolled in a multicentric study from 11 Breast Units.
Methods
Pretreatment blood counts were collected for the analysis and used to calculate NLR and PIV. Logistic regression analyses were performed to evaluate independent predictors of nodal pCR.
Results
A total of 1274 cN+ BC patients were included. Nodal pCR was achieved in 586 (46%) patients. At multivariate analysis, low NLR [odds ratio (OR) = 0.71; 95% CI, 0.51-0.98; p = 0.04] and low PIV (OR = 0.63; 95% CI, 0.44-0.90; p = 0.01) were independently predictive of increased likelihood of nodal pCR. A sub-analysis on cN1 patients (n = 1075) confirmed the statistical significance of these variables. PIV was significantly associated with axillary pCR in estrogen receptor (ER)-/human epidermal growth factor receptor 2 (HER2)+ (OR = 0.31; 95% CI, 0.12-0.83; p = 0.02) and ER-/HER2- (OR = 0.41; 95% CI, 0.17-0.97; p = 0.04) BC patients.
Conclusion
This study found that low NLR and PIV levels predict axillary pCR in patients with BC undergoing NAC.
Registration
Eudract number NCT05798806.
中文翻译：
低中性粒细胞与淋巴细胞比率和泛免疫炎症值预测 1274 名接受新辅助化疗的乳腺癌患者的淋巴结病理完全缓解：一项多中心分析。
背景 全身炎症标志物作为多种肿瘤环境中潜在的基于血液的预后因素引起了极大的兴趣。目的 本研究的目的是评估中性粒细胞与淋巴细胞比值 (NLR) 和泛免疫炎症值 (PIV) 是否可以预测淋巴结阳性 (cN+) 患者新辅助化疗 (NAC) 后的淋巴结病理完全缓解 (pCR)乳腺癌（BC）患者。设计 临床上，接受 NAC 并随后进行乳房和腋窝手术的 cN+ BC 患者被纳入来自 11 个乳腺科的多中心研究。方法收集治疗前的血细胞计数进行分析并计算NLR和PIV。进行逻辑回归分析以评估淋巴结 pCR 的独立预测因子。结果 总共纳入 1274 名 cN+ BC 患者。586 名 (46%) 患者实现了淋巴结 pCR。在多变量分析中，NLR 较低[比值比 (OR) = 0.71；95% CI，0.51-0.98；p = 0.04] 和低 PIV（OR = 0.63；95% CI，0.44-0.90；p = 0.01）独立预测淋巴结 pCR 可能性增加。对 cN1 患者 (n = 1075) 的子分析证实了这些变量的统计显着性。PIV 与雌激素受体 (ER)-/人表皮生长因子受体 2 (HER2)+ 中的腋窝 pCR 显着相关（OR = 0.31；95% CI，0.12-0.83；p = 0.02）和 ER-/HER2-（OR = 0.41；95% CI，0.17-0.97；p = 0.04) BC 患者。结论 本研究发现，低 NLR 和 PIV 水平可预测接受 NAC 的 BC 患者腋窝 pCR。Eudract 注册号 NCT05798806。
更新日期：2023-09-15
中文翻译：
低中性粒细胞与淋巴细胞比率和泛免疫炎症值预测 1274 名接受新辅助化疗的乳腺癌患者的淋巴结病理完全缓解：一项多中心分析。
背景 全身炎症标志物作为多种肿瘤环境中潜在的基于血液的预后因素引起了极大的兴趣。目的 本研究的目的是评估中性粒细胞与淋巴细胞比值 (NLR) 和泛免疫炎症值 (PIV) 是否可以预测淋巴结阳性 (cN+) 患者新辅助化疗 (NAC) 后的淋巴结病理完全缓解 (pCR)乳腺癌（BC）患者。设计 临床上，接受 NAC 并随后进行乳房和腋窝手术的 cN+ BC 患者被纳入来自 11 个乳腺科的多中心研究。方法收集治疗前的血细胞计数进行分析并计算NLR和PIV。进行逻辑回归分析以评估淋巴结 pCR 的独立预测因子。结果 总共纳入 1274 名 cN+ BC 患者。586 名 (46%) 患者实现了淋巴结 pCR。在多变量分析中，NLR 较低[比值比 (OR) = 0.71；95% CI，0.51-0.98；p = 0.04] 和低 PIV（OR = 0.63；95% CI，0.44-0.90；p = 0.01）独立预测淋巴结 pCR 可能性增加。对 cN1 患者 (n = 1075) 的子分析证实了这些变量的统计显着性。PIV 与雌激素受体 (ER)-/人表皮生长因子受体 2 (HER2)+ 中的腋窝 pCR 显着相关（OR = 0.31；95% CI，0.12-0.83；p = 0.02）和 ER-/HER2-（OR = 0.41；95% CI，0.17-0.97；p = 0.04) BC 患者。结论 本研究发现，低 NLR 和 PIV 水平可预测接受 NAC 的 BC 患者腋窝 pCR。Eudract 注册号 NCT05798806。
京公网安备 11010802027423号